Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAD of FXI-GalNAc-siRNA in Healthy Subjects
NCT05844293Phase 1Active, not recruiting
- Sponsor
- Sirnaomics
- Start
- May 2023
- Primary completion
- May 2027
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of RBD4059 in thrombosis (5 cohorts), sponsored by Sirnaomics. Primary endpoints: Maximum peak concentration at 145 days, Time to maximum concentration at 145 days and 4 more. Started May 2023; status: active, not recruiting.
02
Drugs
RBD4059
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT05844293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05844293.